Compare VRAR & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAR | CTXR |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 16.6M |
| IPO Year | 2021 | N/A |
| Metric | VRAR | CTXR |
|---|---|---|
| Price | $1.19 | $0.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.62 | ★ $6.00 |
| AVG Volume (30 Days) | 172.5K | ★ 1.3M |
| Earning Date | 02-12-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,488,209.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $72.00 | $147.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.60 | N/A |
| 52 Week Low | $0.77 | $0.63 |
| 52 Week High | $2.05 | $3.40 |
| Indicator | VRAR | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 59.98 | 40.13 |
| Support Level | $1.03 | $0.74 |
| Resistance Level | $1.17 | $0.99 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 81.08 | 32.71 |
The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.